BG66095B1 - Pregelatinized starch in a controlled release preparation - Google Patents

Pregelatinized starch in a controlled release preparation

Info

Publication number
BG66095B1
BG66095B1 BG10110060A BG11006008A BG66095B1 BG 66095 B1 BG66095 B1 BG 66095B1 BG 10110060 A BG10110060 A BG 10110060A BG 11006008 A BG11006008 A BG 11006008A BG 66095 B1 BG66095 B1 BG 66095B1
Authority
BG
Bulgaria
Prior art keywords
controlled release
hydrophilic
release preparation
pregelatinized starch
preparation
Prior art date
Application number
BG10110060A
Other languages
Bulgarian (bg)
Inventor
Roger Vandecruys
Eugene JANS
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG66095(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of BG66095B1 publication Critical patent/BG66095B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

The invention relates to the use of pregelatinized starch to prevent dumping of the dose of hydrophilic controlled release preparation, as well as to a hydrophilic controlled release preparation, in particular a hydrophilic preparation with controlled release of the matrix, and to solid dosage forms prepared therefrom, preferably for a single daily oral administration. The hydrophilic controlled release preparation contains pregelatinized starch, one or more active ingredients, one or more viscous hydrophilic polymers, and optionally pharmaceutically acceptable formulating agents. The preferred hydrophilic polymers include hydroxypropyl cellulose and hydroxypropyl methylcellulose.
BG10110060A 1999-03-31 2008-02-15 Pregelatinized starch in a controlled release preparation BG66095B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99201018 1999-03-31
PCT/EP2000/002620 WO2000059477A1 (en) 1999-03-31 2000-03-24 Pregelatinized starch in a controlled release formulation

Publications (1)

Publication Number Publication Date
BG66095B1 true BG66095B1 (en) 2011-04-29

Family

ID=8240051

Family Applications (3)

Application Number Title Priority Date Filing Date
BG105857A BG65470B1 (en) 1999-03-31 2001-08-30 Use of pregelatinized starch in a controlled release formulation
BG110060A BG110060A (en) 1999-03-31 2001-08-30 Pregelatinized starch in a controlled release preparation
BG10110060A BG66095B1 (en) 1999-03-31 2008-02-15 Pregelatinized starch in a controlled release preparation

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BG105857A BG65470B1 (en) 1999-03-31 2001-08-30 Use of pregelatinized starch in a controlled release formulation
BG110060A BG110060A (en) 1999-03-31 2001-08-30 Pregelatinized starch in a controlled release preparation

Country Status (27)

Country Link
US (3) US6667060B1 (en)
EP (3) EP1611881A1 (en)
JP (2) JP4928668B2 (en)
KR (3) KR100660594B1 (en)
CN (1) CN1208090C (en)
AT (1) ATE313319T1 (en)
AU (1) AU776645B2 (en)
BG (3) BG65470B1 (en)
BR (1) BR0009437A (en)
CA (1) CA2371940C (en)
CZ (2) CZ300551B6 (en)
DE (1) DE60024981T2 (en)
DK (1) DK1169024T3 (en)
EA (2) EA005291B1 (en)
EE (1) EE05022B1 (en)
ES (2) ES2688273T3 (en)
HK (1) HK1044715B (en)
HR (1) HRP20010700B1 (en)
HU (1) HU230440B1 (en)
IL (3) IL145661A0 (en)
MX (1) MX339071B (en)
NO (2) NO332167B1 (en)
NZ (1) NZ514890A (en)
PL (1) PL198797B1 (en)
SI (1) SI1169024T1 (en)
SK (1) SK288541B6 (en)
WO (1) WO2000059477A1 (en)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1611881A1 (en) * 1999-03-31 2006-01-04 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
CA2428971A1 (en) * 2000-11-14 2003-05-01 New River Pharmaceuticals Inc. Conjugates of a therapeutic agent and a peptide carrier
US20110092677A1 (en) * 2001-08-30 2011-04-21 Biorexis Technology, Inc. Modified transferin-antibody fusion proteins
US8663687B2 (en) * 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7425292B2 (en) * 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20060039958A1 (en) * 2003-05-28 2006-02-23 Monosolrx, Llc. Multi-layer films having uniform content
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
ATE321544T1 (en) * 2001-11-07 2006-04-15 Synthon Bv TAMSULOSINE TABLETS
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
AU2003232398A1 (en) * 2002-06-07 2003-12-22 Ranbaxy Laboratories Limited Sustained release oral dosage forms of gabapentin
US8679533B2 (en) * 2002-07-25 2014-03-25 Pharmacia Corporation Pramipexole once-daily dosage form
AR040680A1 (en) * 2002-07-25 2005-04-13 Pharmacia Corp COMPOSITION OF SUSTAINED RELEASE TABLETS
AR040683A1 (en) * 2002-07-25 2005-04-13 Pharmacia Corp COMPOSITION OF SUSTAINED RELEASE TABLETS INCLUDED BY AN AGONIST OF DOPAMINE RECEIVERS
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
AU2007254665B2 (en) * 2002-07-29 2010-08-19 Alza Corporation Methods and dosage forms for controlled delivery and paliperidone
RU2321391C2 (en) * 2002-07-29 2008-04-10 Алза Корпорейшн Methods and medicinal formulations for controlled delivery of paliperidone
CN100339070C (en) * 2002-10-24 2007-09-26 莫茨药物股份两合公司 Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
BR0317412A (en) * 2002-12-16 2005-11-08 Ranbaxy Lab Ltd Sodium phenytoin prolonged release pharmaceutical composition and process for its preparation
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) * 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
CA2673334C (en) * 2003-06-16 2013-11-12 Andrx Pharmaceuticals, Llc Oral extended-release composition
EP1645568A4 (en) 2003-07-11 2007-06-27 Asahi Kasei Chemicals Corp Functional starch powder
TWI366442B (en) * 2003-07-30 2012-06-21 Novartis Ag Palatable ductile chewable veterinary composition
PL1682537T3 (en) 2003-11-05 2012-09-28 Sarcode Bioscience Inc Modulators of cellular adhesion
US20070292499A1 (en) * 2004-03-10 2007-12-20 Singh Romi B Processes for the Preparation of Solid Dosage Forms of Amorphous Valganciclovir Hydrochloride
EP1734931A2 (en) * 2004-03-24 2006-12-27 Actavis Group Formulations of ramipril
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc Lithium combinations, and uses related thereto
EP1591107A1 (en) * 2004-04-28 2005-11-02 Pfizer GmbH Arzneimittelwerk Gödecke Process for the selective increase of a release rate of an active material from a pharmaceutical composition
JP4185154B2 (en) 2004-04-30 2008-11-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Substituted morpholine compounds for the treatment of central nervous system disorders
TWI338583B (en) 2004-05-20 2011-03-11 Otsuka Pharma Co Ltd Solid pharmaceutical formulation
ATE486588T1 (en) * 2004-08-13 2010-11-15 Boehringer Ingelheim Int EXTENDED RELEASE TABLET FORMULATION CONTAINING PRAMIPEXOLE OR A PHARMACEUTICALLY APPROVED SALT THEREOF, METHOD OF PREPARATION AND USE THEREOF
CA2576386A1 (en) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
ES2330227T3 (en) * 2004-09-09 2009-12-07 Psicofarma, S.A. De C.V. PHARMACEUTICAL COMPOSITION OF PROLONGED HYDRALAZINE RELEASE AND ITS USE AS SUPPORT FOR CANCER TREATMENT.
US20060159742A1 (en) * 2004-11-05 2006-07-20 King Pharmaceutical Research & Development, Inc. Stabilized individually coated ramipril particles, compositions and methods
WO2006052922A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
WO2006052921A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Cyclodextrin solubilizers for liquid and semi-solid formulations
US20060121108A1 (en) * 2004-12-02 2006-06-08 Prasad C K System and method for producing a directly compressible, high-potency formulation of metformin hydrochloride
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
DE05815688T1 (en) * 2005-01-27 2008-06-26 Alembic Ltd. LEVETIRACETAM FORMULATION WITH EXTENDED RELEASE
KR101213345B1 (en) * 2005-04-28 2012-12-17 에자이 알앤드디 매니지먼트 가부시키가이샤 Composition containing anti-dementia drug
JP5794721B2 (en) 2005-05-17 2015-10-14 サーコード バイオサイエンス インコーポレイテッド Compositions and methods for the treatment of ocular disorders
EP2422783B1 (en) * 2005-05-26 2015-04-08 Sumitomo Dainippon Pharma Co., Ltd. Pharmaceutical Composition
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US9192615B2 (en) 2008-08-06 2015-11-24 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
US20080242642A1 (en) 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8252776B2 (en) * 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
DE102005033943A1 (en) * 2005-07-20 2007-02-22 Hexal Ag Non-spitting, oral, fast-disintegrating film for a neuroleptic
EP1927347A4 (en) * 2005-08-10 2011-10-12 Shionogi & Co Bitterness-reducing agent
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
US7803413B2 (en) 2005-10-31 2010-09-28 General Mills Ip Holdings Ii, Llc. Encapsulation of readily oxidizable components
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
DE102006003512A1 (en) * 2006-01-24 2007-08-02 Bayer Schering Pharma Ag Film-forming transmucosal medicament, useful for administering active agents such as androgens, gestagens and estrogens, comprises a film former, which disintegrates in an aqueous medium, and cyclodextrin or its derivatives
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
US20070264346A1 (en) * 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
AP2780A (en) 2006-10-18 2013-09-30 Pfizer Prod Inc Biaryl ether urea compounds
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
ATE513481T1 (en) * 2007-05-23 2011-07-15 Firmenich & Cie FLAVORING COMPOSITION
US20080292683A1 (en) * 2007-05-24 2008-11-27 Monosolrx, Llc. Film shreds and delivery system incorporating same
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EA020466B1 (en) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
MX2009013384A (en) 2007-06-08 2010-01-25 Addrenex Pharmaceuticals Inc Extended release formulation and method of treating adrenergic dysregulation.
PL2155169T3 (en) * 2007-06-08 2016-09-30 Extended release formulation of nevirapine
US9078824B2 (en) * 2007-09-24 2015-07-14 The Procter & Gamble Company Composition and method of stabilized sensitive ingredient
US20090081291A1 (en) * 2007-09-26 2009-03-26 Gin Jerry B Sustained Release Dosage Forms For Delivery of Agents to an Oral Cavity of a User
US20090081294A1 (en) * 2007-09-26 2009-03-26 Gin Jerry B Sustained release dosage form for lubricating an oral cavity
EP2203166B1 (en) * 2007-10-16 2015-05-06 Paladin Labs Inc. Bilayer composition for the sustained release of acetaminophen and tramadol
US8298583B2 (en) 2007-10-19 2012-10-30 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
AU2008317473B2 (en) 2007-10-19 2014-07-17 Bausch + Lomb Ireland Limited Compositions and methods for treatment of diabetic retinopathy
JP5651818B2 (en) 2007-12-17 2015-01-14 パラディン ラブス インコーポレーテッド Controlled release formulation to prevent misuse
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CA2720108C (en) 2008-03-11 2016-06-07 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
FR2928836B1 (en) * 2008-03-21 2011-08-26 Servier Lab SECURE GALENIC FORM FOR MODIFIED RELEASE OF THE ACTIVE INGREDIENT
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
EP2276508A4 (en) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc Delivery of lfa-1 antagonists to the gastrointestinal system
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2724740C (en) * 2008-06-30 2017-02-21 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
AU2013205004B2 (en) * 2008-06-30 2015-08-27 Tocagen Inc. Formulations of 5-fluorocytosine and Uses Thereof
PL2317852T3 (en) * 2008-07-16 2015-05-29 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands
ES2624828T3 (en) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others
EP2317873A4 (en) * 2008-07-22 2015-04-22 Gen Mills Inc Fruit products containing omega-3 fatty acids
US20100040727A1 (en) * 2008-08-18 2010-02-18 Monosol Rx, Llc Method for Improving Uniformity of Content in Edible Film Manufacturing
WO2010055002A1 (en) * 2008-11-17 2010-05-20 Basf Se Starch-containing granular formulation
US8282954B2 (en) * 2008-12-15 2012-10-09 Monosol Rx, Llc Method for manufacturing edible film
AU2009327312A1 (en) 2008-12-16 2011-08-04 Labopharm Europe Limited Misuse preventative, controlled release formulation
GEP20146013B (en) 2009-01-23 2014-01-27 Aziende Chimiche Riunite Angelini Francesco A C R A F S P A It Controlled release pharmaceutical or food formulation and method of preparation thereof
EP3045043B1 (en) 2009-02-26 2020-04-29 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
US20100285130A1 (en) * 2009-05-06 2010-11-11 Monosol Rx, Llc Coating of complexed actives in film formulations
US20100297232A1 (en) * 2009-05-19 2010-11-25 Monosol Rx, Llc Ondansetron film compositions
MX340134B (en) 2009-07-09 2016-06-28 Oshadi Drug Administration Ltd Matrix carrier compositions, methods and uses.
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
US20110142942A1 (en) * 2009-12-10 2011-06-16 Monosol Rx, Llc USE OF pH SENSITIVE COMPOUNDS IN TASTE MASKING OF DRUG SUBSTANCES WITHIN ORAL THIN FILM STRIPS
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
CN102892405A (en) * 2009-12-28 2013-01-23 莫诺索尔克斯有限公司 Orally administrable film dosage forms containing ondansetron
KR101484382B1 (en) * 2010-02-24 2015-01-19 조에티스 엘엘씨 Veterinary compositions
US8975387B1 (en) 2010-03-22 2015-03-10 North Carolina State University Modified carbohydrate-chitosan compounds, methods of making the same and methods of using the same
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
US20130267612A1 (en) * 2010-12-21 2013-10-10 Akzo Nobel Chemicals International B.V. Instant powders for aqueous cosmetic applications
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
JP5960523B2 (en) * 2012-06-29 2016-08-02 旭化成株式会社 Solid formulation consisting of modified starch and dissolution control agent
AU2013295706A1 (en) 2012-07-25 2015-02-19 Sarcode Bioscience Inc. LFA-1 inhibitor and polymorph thereof
EP2883538A1 (en) * 2012-07-27 2015-06-17 Taisho Pharmaceutical Co., Ltd. Composition for agent for external use
EP2958577A2 (en) 2013-02-25 2015-12-30 Synergy Pharmaceuticals Inc. Guanylate cyclase receptor agonists for use in colonic cleansing
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP3054969B1 (en) 2013-10-10 2021-03-10 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
US9561187B1 (en) * 2014-02-03 2017-02-07 CMAX Technologies, Inc. Sustained release metoprolol formulations
US10344037B2 (en) 2014-03-26 2019-07-09 Canget BioTek Pharma LLC Use of the FL-one hundred eighteen core chemical structure platform to generate FL-one hundred eighteen derivatives for treatment of human disease
CN103948550A (en) * 2014-04-22 2014-07-30 青岛市市立医院 Cisapride dispersible tablet and preparation method thereof
CA2950148C (en) 2014-06-02 2022-07-12 Tethis, Inc. Modified biopolymers and methods of producing and using the same
BE1021194B1 (en) * 2014-07-07 2015-07-14 Nordic Specialty Pharma Bvba PARACETAMOL TABLETS
MX2018006309A (en) 2015-11-23 2019-09-04 Tethis Inc Coated particles and methods of making and using the same.
WO2017123634A1 (en) 2016-01-11 2017-07-20 Synergy Pharmaceuticals, Inc. Formulations and methods for treating ulcerative colitis
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
JP2019519487A (en) 2016-05-05 2019-07-11 アクエスティブ セラピューティクス インコーポレイテッド Delivery enhancing epinephrine composition
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
CN107198680A (en) * 2016-10-12 2017-09-26 钟术光 Sustained release preparation
JP7426685B2 (en) * 2018-06-14 2024-02-02 株式会社東洋新薬 tablet
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
GB2606585B (en) * 2021-03-31 2024-02-14 Tate & Lyle Solutions Usa Llc Pregelatinized inhibited hollow starch products and methods of making and using them

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2195893A (en) * 1986-10-09 1988-04-20 Sandoz Ltd Sustained release composition
EP0280613A1 (en) * 1987-02-18 1988-08-31 Pierre Fabre Medicament Dihydroergotamine (D.H.E.) tablet of the hydrophilic-matrix type, and process for its production
EP0477061A1 (en) * 1990-09-07 1992-03-25 Pierre Fabre Medicament Tablet of Isosorbide-5-Mononitrate with sustained release and its process of preparation
WO1996014070A1 (en) * 1994-11-02 1996-05-17 Janssen Pharmaceutica N.V. Cisapride extended release oral compositions
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
WO1997024109A1 (en) * 1995-12-27 1997-07-10 Janssen Pharmaceutica N.V. Bioadhesive solid dosage form

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
JPS615027A (en) * 1984-06-18 1986-01-10 Sadahiro Nakano Sustained release solid pharmaceutical
US4806359A (en) * 1987-04-22 1989-02-21 Mcneilab, Inc. Iburprofen sustained release matrix and process
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
FR2618073B1 (en) * 1987-07-16 1990-09-07 Pf Medicament HYDROPHILIC MATRIX-TYPE TABLETS BASED ON SALBUTAMOL AND THEIR PREPARATION METHOD
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
US5534496A (en) * 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
AU6251094A (en) * 1993-02-26 1994-09-14 Procter & Gamble Company, The Bisacodyl dosage form
US5698226A (en) 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
US5635208A (en) 1993-07-20 1997-06-03 Mcneil-Ppc, Inc. Granulation process for producing an acetaminophen and diphenhydramine hydrochloride composition and composition produced by same
TW349870B (en) 1993-09-30 1999-01-11 Janssen Pharmaceutica Nv An antifungal pharmaceutical composition for oral administration and a process for the preparation thereof
JPH07204796A (en) * 1994-01-14 1995-08-08 Kawasaki Steel Corp Apparatus for production of thin metallic strip
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
US5972373A (en) * 1995-05-02 1999-10-26 Taisho Pharmaceutical Co., Ltd. Taste masking pharmaceutical composition for oral administration
JPH0952832A (en) * 1995-08-10 1997-02-25 Takeda Chem Ind Ltd Medicinal composition
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
HU229240B1 (en) * 1998-09-26 2013-10-28 Sanofi Aventis Deutschland Method for production of alpha,alpha-dimethylphenyl acetic acid from alpha,alpha-dimethyl benzyl cyanide
EP1611881A1 (en) * 1999-03-31 2006-01-04 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2195893A (en) * 1986-10-09 1988-04-20 Sandoz Ltd Sustained release composition
EP0280613A1 (en) * 1987-02-18 1988-08-31 Pierre Fabre Medicament Dihydroergotamine (D.H.E.) tablet of the hydrophilic-matrix type, and process for its production
EP0477061A1 (en) * 1990-09-07 1992-03-25 Pierre Fabre Medicament Tablet of Isosorbide-5-Mononitrate with sustained release and its process of preparation
WO1996014070A1 (en) * 1994-11-02 1996-05-17 Janssen Pharmaceutica N.V. Cisapride extended release oral compositions
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
WO1997024109A1 (en) * 1995-12-27 1997-07-10 Janssen Pharmaceutica N.V. Bioadhesive solid dosage form

Also Published As

Publication number Publication date
CA2371940A1 (en) 2000-10-12
CN1345233A (en) 2002-04-17
NZ514890A (en) 2003-05-30
HK1044715B (en) 2006-02-17
CZ307700B6 (en) 2019-02-20
CZ300551B6 (en) 2009-06-17
BR0009437A (en) 2002-01-15
CN1208090C (en) 2005-06-29
SK288541B6 (en) 2018-03-05
MX339071B (en) 2016-05-09
EA005291B1 (en) 2004-12-30
IL145661A0 (en) 2002-06-30
JP4928668B2 (en) 2012-05-09
DE60024981T2 (en) 2006-09-14
EE200100505A (en) 2002-12-16
CA2371940C (en) 2008-07-15
CZ2006443A3 (en) 2019-02-20
KR100660594B1 (en) 2006-12-22
NO332167B1 (en) 2012-07-09
PL355096A1 (en) 2004-03-22
ATE313319T1 (en) 2006-01-15
IL219820A0 (en) 2012-06-28
IL145661A (en) 2013-10-31
DK1169024T3 (en) 2006-05-08
AU776645B2 (en) 2004-09-16
NO20111249L (en) 2001-09-28
ES2688273T3 (en) 2018-10-31
BG110060A (en) 2008-12-30
US8591945B2 (en) 2013-11-26
US20040062805A1 (en) 2004-04-01
KR20060097068A (en) 2006-09-13
JP2002541090A (en) 2002-12-03
HU230440B1 (en) 2016-06-28
EP1611881A1 (en) 2006-01-04
NO20014724L (en) 2001-09-28
DE60024981D1 (en) 2006-01-26
US20090191266A1 (en) 2009-07-30
KR20020002384A (en) 2002-01-09
EP1649851A3 (en) 2008-04-23
NO20014724D0 (en) 2001-09-28
BG65470B1 (en) 2008-09-30
HRP20010700B1 (en) 2011-01-31
EA200101026A1 (en) 2002-06-27
JP2011006485A (en) 2011-01-13
WO2000059477A1 (en) 2000-10-12
HK1044715A1 (en) 2002-11-01
CZ20013375A3 (en) 2002-05-15
BG105857A (en) 2002-04-30
EP1649851B1 (en) 2018-06-20
MXPA01009877A (en) 2002-05-06
SK13542001A3 (en) 2002-08-06
EE05022B1 (en) 2008-06-16
PL198797B1 (en) 2008-07-31
EA200401009A1 (en) 2004-12-30
NO342239B1 (en) 2018-04-23
EP1649851A2 (en) 2006-04-26
HUP0200611A2 (en) 2002-07-29
SI1169024T1 (en) 2006-06-30
HUP0200611A3 (en) 2003-04-28
HRP20010700A2 (en) 2003-04-30
EP1169024A1 (en) 2002-01-09
US6667060B1 (en) 2003-12-23
KR20100036398A (en) 2010-04-07
EP1169024B1 (en) 2005-12-21
AU3963800A (en) 2000-10-23
ES2255490T3 (en) 2006-07-01

Similar Documents

Publication Publication Date Title
BG66095B1 (en) Pregelatinized starch in a controlled release preparation
EP0966966A3 (en) Nefazodone dosage form
RS20090134A (en) Pharmaceutical combinattion of ethinylestradiol and drospinenone for use as a contraceptive
YU33099A (en) Pharmaceutical composition
AP1954A (en) Controlled release compositions comprising nimesulide.
BR0015188A (en) Pharmaceutical compositions
AU1079701A (en) Oral transmucosal drug dosage using solid solution
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
AU2003238221A1 (en) Ibuprofen suspension
AP2003002763A0 (en) Controlled release formulations for oral administration
NO327588B1 (en) Pharmaceutical composition and composition comprising ethinylostradiol and drospirenone for use as a contraceptive
WO2002011694A3 (en) Compositions and dosage forms for application in the oral cavity in the treatment of mykoses
ES2130081B1 (en) TRIMEBUTINE MALEATE TABLET WITH LAMINAR COATING.
HUP0203148A2 (en) Orally distintegrating composition comprising mirtazapine
EA200701091A1 (en) OPTICAL PHARMACEUTICALS
AU2502301A (en) Medicament and combination of compatible medicaments
JO2213B1 (en) A pharmaceutical composition for use as a contraceptive
DE50311479D1 (en) PHARMACEUTICAL COMPOSITION, CONTAINING OXCARBAZEPINE WITH CONTROLLED ACTIVE INGREDIENTS